| Reaction Details |
|---|
 | Report a problem with these data |
| Target | 5-hydroxytryptamine receptor 2A |
|---|
| Ligand | BDBM50001915 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_609158 (CHEMBL1066141) |
|---|
| Ki | 48±n/a nM |
|---|
| Citation |  Ahmad, S; Ngu, K; Miller, KJ; Wu, G; Hung, CP; Malmstrom, S; Zhang, G; O'Tanyi, E; Keim, WJ; Cullen, MJ; Rohrbach, KW; Thomas, M; Ung, T; Qu, Q; Gan, J; Narayanan, R; Pelleymounter, MA; Robl, JA Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett20:1128-33 (2010) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| 5-hydroxytryptamine receptor 2A |
|---|
| Name: | 5-hydroxytryptamine receptor 2A |
|---|
| Synonyms: | 5-HT-2 | 5-HT-2A | 5-HT2A | 5-hydroxytryptamine receptor 2A (5-HT-2A) | 5-hydroxytryptamine receptor 2A (5HT-2A) | 5-hydroxytryptamine receptor 2A (5HT2A) | 5HT2A_HUMAN | HTR2 | HTR2A | Serotonin receptor 2A |
|---|
| Type: | undefined |
|---|
| Mol. Mass.: | 52607.65 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P28223 |
|---|
| Residue: | 471 |
|---|
| Sequence: | MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC
LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD
MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP
IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF
VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH
REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA
LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV
|
|
|
|---|
| BDBM50001915 |
|---|
| n/a |
|---|
| Name | BDBM50001915 |
|---|
| Synonyms: | 1-(3-chlorophenyl)piperazine | CHEMBL478 | m-Chlorophenylpiperazine | mCPP |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C10H13ClN2 |
|---|
| Mol. Mass. | 196.677 |
|---|
| SMILES | Clc1cccc(c1)N1CCNCC1 |
|---|
| Structure | 
|
|---|
Search and Browse
